Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea · Delayed Price · Currency is KRW 13,900
-250 (-1.77%)
Apr 10, 2026, 3:30 PM KST
Hyundai Bioscience Revenue
In the year 2025, Hyundai Bioscience had annual revenue of 3.52B KRW, down -76.63%.
Revenue
3.52B
Revenue Growth
-76.63%
P/S Ratio
386.34
Revenue / Employee
50.98M
Employees
69
Market Cap
1.36T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.52B | -11.53B | -76.63% |
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| GC Biopharma | 1.99T |
| Chong Kun Dang Pharmaceutical | 1.69T |
| Chabiotech | 1.27T |
| DongKook Pharmaceutical | 926.88B |
| HK inno.N | 839.63B |